2026-03-30 05:15Summary of the Conference Call on Preclinical CRO Industry Industry Overview - The preclinical Contract Research Organization (CRO) sector is experiencing a significant surge in orders, with a full recovery expected by Q4 2025. Orders are projected to increase by tens of percentage points year-on-year in H1 2026, potentially doubling the order value due to both volume and price increases [1][2]. Core Insights and Arguments - Service Price Recovery: Rapid recovery in service prices has been noted, particularly in the safety evaluation sector, where discounts have narrowed from 50% to no discount, resulting in year-on-year price increases of several tens of percentage points. This price increase is expected to translate directly into profits [1][2]. - Monkey Resource Supply Shortage: A critical factor driving the increase in service prices is the shortage of monkey resources, exacerbated by slow import approval processes. This shortage has led to a dramatic rise in monkey prices, which in turn has pushed up service fees [3]. - BD Transaction Activity: The active business development (BD) transactions are concentrating research and development investments in the preclinical phase. High-value orders are expected to be fully reflected in financial reports by Q3 2026, with net profits anticipated to return to 2021 peak levels by Q1 2027 [1][4]. Future Outlook - Order Sustainability: There are no immediate concerns regarding order sustainability. Orders are expected to show strong performance in Q1 and Q2 of 2026, with projected year-on-year growth of several tens of percentage points. The overall order amount may double due to the combined effect of increased order volume and service price hikes [4]. - Profit Margin Impact: The rapid increase in order prices is expected to significantly enhance profit margins for related companies. The price improvement began in Q3 2025, with discounts narrowing from 50-60% to 80-90%. This price increase is anticipated to be reflected in financial statements starting Q3 2026, with some companies potentially reaching net profit levels close to the peak of 2021 by Q1 2027 [5][6]. Key Companies to Watch - InnoCare Pharma: Recommended due to its low correlation with the domestic market and strong order certainty in Q1 and Q2 of 2026. Its smaller market capitalization provides significant upside potential [7]. - Zhaoyan New Drug: Despite facing a reduction event, it presents a good entry point. The profit levels in 2027 are expected to match or exceed those of 2021, with considerable room for growth compared to previous peaks [7]. - Medpace: As a leading integrated preclinical service provider, it is currently benefiting from the focus on safety evaluation. As the industry continues to improve, its front-end services are expected to gain traction, revealing its performance elasticity [7]. Overall Market Trend - The current market situation is just the beginning, driven by improved BD conditions for innovative drugs in 2025. Although there have been significant stock adjustments due to rising monkey prices and corrections in the innovative drug sector, the current position offers a favorable entry point for investors. Continued healthy development of the Chinese innovative drug industry is expected to benefit domestic CRO companies, with potential for greater valuation expansion if orders remain strong in the second half of the year [8][9].